Abstract | OBJECTIVE: The combination of GEM/ PLD has been tested for its efficacy on survival of recurrent ovarian cancer patients. METHODS: This is a multicenter phase II study of GEM/ PLD regimen in recurrent ovarian cancer patients previously treated with at least one platinum/ paclitaxel regimen, and with evidence of measurable disease. PLD, 30 mg m(-2), was administered on day 1 followed by GEM, 1000 mg m(-2), on days 1 and 8, every 21 days. RESULTS: 106 patients were available for response evaluation. 9 complete responses (8.5%) and 27 partial responses (25.5%) have been registered. 36 patients (34.0%) experienced stabilization of disease, while 34 (32.1%) cases progressed during treatment. OS was significantly shorter in platinum-resistant (median OS = 50 weeks) than in platinum-sensitive patients (median OS = 92 weeks) (P value = 0.0016). In the group of platinum-sensitive patients, cases responsive to GEM/ PLD combination showed a better OS with respect to patients unresponsive to GEM/ PLD (median OS = 120 weeks versus median OS = 60 weeks, P value = 0.019). The same trend was observed in platinum-resistant patients. Grade 4 hematological toxicity affected 20 patients (18%). Grade 3 palmar-plantar erythrodysesthesia (PPE) was registered in 16 patients (14.4%). Grades 3 and 4 mucositis was documented in 16 (14.4%) and 2 (1.8%) patients, respectively. CONCLUSIONS: GEM/ PLD combination represents a valid approach in recurrent ovarian cancer patients. The hematological toxicity was easily managed, and the incidence and severity of PPE was low.
|
Authors | Gabriella Ferrandina, Ida Paris, Manuela Ludovisi, Giuseppe D'Agostino, Antonia Testa, Domenica Lorusso, Mariangela Zanghi, Salvatore Pisconti, Giuseppa Pezzella, Vincenzo Adamo, Enrico Breda, Giovanni Scambia |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 98
Issue 2
Pg. 267-73
(Aug 2005)
ISSN: 0090-8258 [Print] United States |
PMID | 15975643
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Deoxycytidine
- Doxorubicin
- Gemcitabine
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Deoxycytidine
(administration & dosage, adverse effects, analogs & derivatives)
- Doxorubicin
(administration & dosage, adverse effects)
- Drug Administration Schedule
- Female
- Humans
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Ovarian Neoplasms
(drug therapy)
- Salvage Therapy
- Survival Rate
- Gemcitabine
|